indazoles has been researched along with fulvestrant in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Bates, D; Bean, JR; Demidenko, E; Dillon, LM; Eastman, AR; Hosford, SR; Lewis, LD; Liu, SC; Marotti, JD; Miller, TW; Nannini, MA; Pang, J; Salphati, L; Shee, K; Yang, W; Zhang, X | 1 |
| Aimi, J; Amler, LC; Chan, IT; Chen, M; Derynck, MK; Gendreau, S; Hampton, GM; Johnston, S; Krop, I; Lackner, MR; Qiu, J; Savage, H; Schmid, P; Spoerke, JM; Walter, K; Wilson, TR | 1 |
| Blake, RA; Chalouni, C; Chen, IP; Daemen, A; De Bruyn, T; Friedman, LS; Giltnane, JM; Guan, J; Hafner, M; Hager, JH; Hartman, SJ; Heidersbach, A; Houtman, R; Ingalla, E; Kategaya, L; Kleinheinz, T; Li, J; Martin, SE; Metcalfe, C; Modrusan, Z; Nannini, M; Oeh, J; Sampath, D; Ubhayakar, S; Wang, X; Wertz, IE; Young, A; Yu, M; Zhou, W | 1 |
| Ala-Hongisto, H; Bertula, K; Elo, LL; Euro, L; Heikkilä, P; Hollmann, B; Hukkinen, K; Ikkala, O; Joensuu, H; Junttila, MR; Kivento, M; Klefström, J; Kovanen, P; Leidenius, M; Martikainen, L; Mattson, J; Meretoja, T; Metcalfe, C; Monni, O; Munne, PM; Mutka, M; Nevalaita, L; Patrikainen, L; Peura, A; Pokki, J; Pouwels, J; Räty, I; Ruuska, J; Sahu, B; Salmela, M; Suomi, T; Väänänen, J; Yavuz, K | 1 |
| Aithal, KB; Albacker, LA; Banka, D; Bolduc, DM; Furman, C; Hao, MH; Irwin, S; Kim, A; Korpal, M; Larsen, N; Montesion, M; Moriarty, AD; Murugesan, K; Nguyen, TV; Prajapati, S; Puyang, X; Rimkunas, V; Sahmoud, T; Vaillancourt, FH; Wick, MJ; Wu, ZJ; Yao, S; Zeng, H; Zhang, X; Zhang, Z; Zheng, GZ; Zhu, P | 1 |
2 trial(s) available for indazoles and fulvestrant
| Article | Year |
|---|---|
Pictilisib stalls advanced ER+/PR+ breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Estradiol; Female; Fulvestrant; Humans; Indazoles; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Receptors, Estrogen; Receptors, Progesterone; Sulfonamides | 2015 |
Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Disease-Free Survival; DNA Mutational Analysis; DNA, Neoplasm; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Antagonists; Estrogens; Female; Fulvestrant; Humans; Indazoles; Middle Aged; Mutation; Protein Kinase Inhibitors; Sulfonamides | 2016 |
4 other study(ies) available for indazoles and fulvestrant
| Article | Year |
|---|---|
Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, PIK3CA-Mutant Breast Cancer.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Indazoles; MCF-7 Cells; Mice; Mice, Inbred NOD; Mutation; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Signal Transduction; Sulfonamides; Therapeutic Index | 2016 |
Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility.
Topics: Animals; Breast Neoplasms; Cell Proliferation; Cinnamates; Drug Resistance, Neoplasm; Estrogen Receptor Antagonists; Female; Fulvestrant; HEK293 Cells; Heterografts; Humans; Indazoles; Ligands; MCF-7 Cells; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Polymorphism, Single Nucleotide; Proteolysis; Receptors, Estrogen; Signal Transduction; Transcription, Genetic | 2019 |
Compressive stress-mediated p38 activation required for ERα + phenotype in breast cancer.
Topics: Breast Neoplasms; Case-Control Studies; Cell Line, Tumor; Cinnamates; Collagen; Drug Combinations; Enhancer of Zeste Homolog 2 Protein; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Histones; Humans; Indazoles; Laminin; Mammary Glands, Human; Mechanotransduction, Cellular; p38 Mitogen-Activated Protein Kinases; Phenotype; Proteoglycans; Tamoxifen; Tissue Culture Techniques; Transcriptome | 2021 |
Covalent ERα Antagonist H3B-6545 Demonstrates Encouraging Preclinical Activity in Therapy-Resistant Breast Cancer.
Topics: Breast Neoplasms; Clinical Trials as Topic; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Indazoles; Neoplasm Recurrence, Local; Pyridines | 2022 |